Telomir Pharmaceuticals, a preclinical developer of an oral small molecule therapy for hemochromatosis, raised $7 million by offering 1.0 million shares at $7.00, in line with its latest filing. The Baltimore, MD-based company is focused on the development and...read more
Telomir Pharmaceuticals, a preclinical biotech developing an oral small molecule for age- and cancer-related conditions, announced terms for its IPO on Thursday. The Baltimore, MD-based company plans to raise $7 million by offering 1 million shares at $7. At...read more
Telomir Pharmaceuticals, a preclinical biotech developing an oral small molecule for age- and cancer-related conditions, filed on Tuesday with the SEC to raise up to $14 million in an initial public offering. Telomir Pharmaceuticals is focused on the...read more
US IPO Weekly Recap: Autoimmune biotech Kyverna Therapeutics gains 37% in a 6 IPO week
Six IPOs priced this past week, joined by two blank check companies. One larger deal did not get done: Fortegra (TFG) ...read more
Hemochromatosis drug developer Telomir Pharmaceuticals prices IPO at $7
Telomir Pharmaceuticals, a preclinical developer of an oral small molecule therapy for hemochromatosis, raised $7 million by offering 1.0 million shares at $7.00, in line with its latest filing. The Baltimore, MD-based company is focused on the development and...read more
Small molecule biotech Telomir Pharmaceuticals sets terms for $7 million IPO
Telomir Pharmaceuticals, a preclinical biotech developing an oral small molecule for age- and cancer-related conditions, announced terms for its IPO on Thursday. The Baltimore, MD-based company plans to raise $7 million by offering 1 million shares at $7. At...read more
Small molecule biotech Telomir Pharmaceuticals files for a $14 million IPO
Telomir Pharmaceuticals, a preclinical biotech developing an oral small molecule for age- and cancer-related conditions, filed on Tuesday with the SEC to raise up to $14 million in an initial public offering. Telomir Pharmaceuticals is focused on the...read more